Abstract:
An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.
Abstract:
An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
Abstract:
A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF encode for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5′ and 3′ ITRs flank the expression cassettes and regulatory sequences.
Abstract:
A method of altering the targeting and/or cellular uptake efficiency of an adeno-associated virus (AAV) viral vector having a capsid containing an AAV9 cell surface binding domain is described. The method involves modifying a clade F cell surface receptor which comprises a glycan having a terminal sialic acid residue and a penultimate β-galactose residue. The modification may involve retargeting the vector by temporarily functionally ablate AAV9 binding in a subset of cells, thereby redirecting the vector to another subset of cells. Alternatively, the modification may involve increasing cellular update efficiency by treating the cells with a neuraminidase to expose cell surface β-galactose. Also provided are compositions containing the AAV9 vector and a neuraminidase. Also provided is a method for purifying AAV9 using β-galactose linked to solid support. Also provided are mutant vectors which have been modified to alter their targeting specificity, including mutant AAV9 in which the galactose binding domain is mutated and AAV in which an AAV9 galactose binding domain is engineered.
Abstract:
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: and wherein R1–R5 and Q1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a compound of formula I and a selective estrogen receptor modulator are also described.
Abstract:
In a pivoting guide for a traveling transmission chain, composed of a synthetic resin body having a shoe and a slotted reinforcement, and a plate fitting into the slot, the plate has a mounting hole received on a boss formed on the guide body and coaxial with a mounting hole on the guide body which receives a pivot shaft. This structure facilitates assembly and mounting because the plate is securely attached to the guide body before the assembly is mounted. The plate does not contact the pivot shaft, and therefore full advantage is taken of the self-lubricating property of the synthetic resin. The boss may be elongated so that the length of the mounting hole of the guide body is greater than the width of the shoe so that wear in of the guide body due to biased loads is dispersed, and the useful life of the guide is extended.
Abstract:
The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds having the general structures below: which are useful in treating uterine leiomyoma.
Abstract:
An environmentally-friendly process for applying a chrome finish on a substrate is provided. The chrome finish comprises a thin film of aluminum and chromium deposited onto the substrate by physical vapor deposition (PVD) techniques. The thin layer can consist of three separately deposited metallic layers including a chromium layer sandwiched between a pair of aluminum layers or can consist of a single, simultaneously co-deposited layer of aluminum and chromium in a ratio of 10% to 70% by weight chromium and 30% to 90% aluminum. The structure of a coated substrate is also disclosed.
Abstract:
In a roller chain, the outside diameters D of the rollers and the outside diameters d of the pins extending through bushings on which the rollers are disposed satisfy the relationships 0.72P≦D≦0.79P and 0.40P≦d≦0.44P where P is the pitch of the roller chain. The height H of the inner plates of the chain satisfies the relationship 0.96P≦H. The elongation ratio of the chain is significantly reduced, and improvements in breaking strength of the pin and in the rotational fatigue of the chain are realized. Consequently wear resistance, strength, and endurance of the chain are significantly improved, making the chain suitable for use as a timing chain in an engine that rotates at high speed.
Abstract translation:在滚子链中,滚子的外径D和延伸穿过其上布置的套管的销的外径d满足关系0.72P <= D <= 0.79P和0.40P <= d <= 0.44 P其中P是滚子链的间距。 链条内板的高度H满足0.96P <= H的关系。 链的伸长率显着降低,并且实现了销的断裂强度和链的旋转疲劳的提高。 因此,链条的耐磨性,强度和耐久性得到显着提高,使链条适用于在高速旋转的发动机中的正时链条。